Costs of Drug Development Revisited

Yevgeniy Feyman of Forbes has written an intriguing article entitled “Shocking Secrets of FDA Clinical Trials Revealed” the costs of bringing a new drug to market.  Feyman shares that “according to Joseph Dimasi of the Tufts Center for the Study of Drug Development, on average, the capitalized cost comes out to about $1.3 billion.  He sites that FDA, difficulties with clinical trials, and the fact that the majority of common illnesses have already been cured or prevented have driven up these costs.  So many companies have now turned their focus on curing “orphan diseases” (diseases that impact a small portion of the population). He also shares insights into the fact.  He even covers the topics of surrogate endpoints, FDA’s Accelerated Approval Path, and post market surveillance pressures.  To read the full article click here.